Other studies found that cfDNA can include 15%-20% of ctDNA, depending on tumor stage and tumor burden, but localized prostate cancers typically remain below the threshold for detection of ctDNA, whereas prostate-specific antigen (PSA), a protein marker that is not uniquely an indicator for cancer, is already at a high-risk level[91]. The gene discussed is KLK3; the disease is neoplasm.